David Heredia, Head of the Oncology Department at Punta Medica, shared a post on X:
”In the real-world LEOPARD study (stage III NSCLC): 56% recurred after chemoradiotherapy plus Durvalumab.
Timing:
- 53% within first 12 cycles,
- 25% between 12–24,
- 22% after 24 cycles.
72% had oligorecurrence.
Most relapses were limited and early, suggesting opportunity for local approaches.”
Title: Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial)
Authors: P. Ciammella, F. Iori, P. Borghetti, M. Galaverni, E. Alì, M. Tiseo, M. Pagano, M. Sepulcri, V. Scotti, N. Giaj Levra, M. Marcenaro, N. Simoni, V. Nardone, A. Bottin, S. Cozzi, A. Bruni
You can read the Full Article on Lung Cancer.
More posts featuring David Heredia.